P/E ratio for OncoCyte (OCX)
P/E ratio as of April 2024 (TTM): -0.2410
According to OncoCyte 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.240993. At the end of 2022 the company had a P/E ratio of -0.0242.
P/E ratio history for OncoCyte from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.0242 | -84.18% |
| 2021 | -0.1528 | -41.18% |
| 2020 | -0.2598 | -0.71% |
| 2019 | -0.2616 | 59.25% |
| 2018 | -0.1643 | -54.78% |
| 2017 | -0.3633 | -55.68% |
| 2016 | -0.8198 | 74.01% |
| 2015 | -0.4711 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | -3.70 | 1,437.03% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.